SGRY Surgery Partners Forward P/S Multiple
Diversification across numerous specialties and US regions mitigates risks for Surgery Partners, Inc. (SGRY), although profits rely on insurance reimbursements and surgeon flow. The forward price-to-sales ratio helps evaluate these factors, with the current level sitting around 1.00. A narrow specialization in ambulatory surgery centers is offset by the global trend toward affordable, short-term procedures.
Comprehensive metric breakdowns and analytics for Surgery Partners Group (SGRY)
- current price and projected stock value:
- market capitalization data:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Equity Ratio Surgery Partners, Inc.|SGRY - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Surgery Partners, Inc.|SGRY - Company Aggregate Indebtedness|Debts to Book Capitalization Surgery Partners Group|SGRY - Company Long-Term Debts|Company Short-Term Debt Surgery Partners|Quick Liquidity Indicator surgerypartners.com
- business earnings and investment ratios data:
SGRY - Profit After Payment of Taxes|Expected Profit Surgery Partners, Inc.|SGRY - Price to Earnings Multiple|Forward P/E Multiple Surgery Partners Corp|SGRY - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Surgery Partners Group|SGRY - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Surgery Partners|SGRY - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months surgerypartners.com|SGRY - Earnings per share increase in current year|Earnings growth forecast for next year Surgery Partners, Inc.
- company sales and revenue statistics:
Fundamental valuation:Surgery Partners SGRY
Investors value the scalability of Surgery Partners, Inc. (SGRY), where high center utilization optimizes costs and increases the margin of each procedure. The current forward P/S ratio reflects market capitalization relative to expected annual revenue, allowing for the daily tracking of business revaluation between reports. The growth of this indicator confirms market confidence in the efficiency of the operating model and the long-term strength of the issuer's position.
Competitors of Surgery Partners, Inc.
Forward P/S Multiple HCA (HCA Healthcare)|Projected Price to Revenue Tenet Healthcare Corp|Fresenius Medical Care Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Solventum Health|Encompass Health (EHC) - Price-to-Projected Revenue Ratio|Universal Health Services, Inc. - Forward Price to Sales|Forward Price-to-Revenue Multiple DVA|Market Cap to Future Revenue Ratio RadNet Inc RDNT|Forward Price-to-Revenue Multiple OPCH (Option Care Health Inc)|PINC (Premier Health) - Forward Price to Sales|Price-to-Projected Revenue Ratio National Vision Holdings EYE|PGNY (progyny.com) - Future Price to Revenue|Ardent Health Partners - Forward P/S Multiple|SEM - Forward P/S Multiple|Apollo Medical Holdings (ASTH) - Price-to-Projected Revenue Ratio|MEDNAX - Forward Price to Sales|Forward Price-to-Revenue Multiple USPH|PNTG (pennantgroup.com) - Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio Organogenesis (ORGO)|Nutex Health Inc - Market Cap to Projected Revenue|Forward P/S Multiple AUNA (Auna Health)|SBC Medical Group Holdings (SBC) - Market Cap to Future Revenue Ratio|EOLS - Price-to-Projected Revenue Ratio|Forward Price to Sales CYH (chs.net)|beautyhealth.com (SKIN) - Price-to-Projected Revenue Ratio|MDWD - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple BTMD|JYNT: Forward Price to Sales|Forward P/S Multiple DCGO|Market Cap to Expected Sales Ratio p3hp.org|Price-to-Projected Revenue Ratio Gain Therapeutics GANX|EUDA: Market Cap to Projected Revenue|Basel Medical Group Limited - Forward P/S Multiple|CollPlant Biotechnologies (CLGN) - Forward Price-to-Revenue Multiple|CUPR (Cuprina Holdings (Cayman) Ltd) - Forward Price-to-Revenue Multiple|CCM - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio American Shared Hospital Services|MEDIROM Healthcare Group Inc. (MRM) - Market Cap to Expected Sales Ratio|Forward P/S Multiple ALBT|DIH Group (DHAI) - Projected Price to Revenue|Price-to-Projected Revenue Ratio Longevity Health Holdings XAGE|Forward Price to Sales NIVF|ATIP: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio CareMax Inc.|KDLY (Kindly MD Corp) - Forward Price-to-Revenue Multiple|MODV: Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio Novo Integrated Sciences|SSY: Forward Price to Sales|Forward P/S Multiple BACK
